Lifeasible, a biotechnology company specializing in agricultural applications, has officially introduced a new plant recombinant antibody expression service. This addition to the company’s plant-based technology portfolio aims to provide a cost-effective, scalable, and biosafe solution for antibody production using plant systems.
The expression of recombinant antibodies in plants—commonly known as “plantibodies”—has gained increasing attention as a viable alternative to traditional mammalian or microbial systems. Plants offer several benefits, including low production costs, minimized risk of animal-derived pathogen contamination, and rapid biomass generation. These advantages make plant-based systems particularly attractive for both research and industrial-scale production.
Lifeasible’s new service includes both transient and stable expression options, enabling flexible solutions depending on the client’s objectives. Transient expression is suitable for short-term studies and rapid testing, while stable transformation supports long-term, consistent antibody yields. The process involves advanced vector design, efficient gene delivery methods such as Agrobacterium-mediated transformation and gene gun techniques, followed by downstream purification and validation procedures.
Key features of the plant recombinant antibody expression service include:
- Custom gene synthesis and vector construction with optimized promoters and selection markers
- Transient or stable transformation using host plants such as Nicotiana benthamiana
- Scalable cultivation systems for biomass accumulation
- Protein purification and quality validation using chromatography and activity assays
According to Lifeasible, this platform is designed to accommodate projects at different scales, from early-stage research to large-batch production. Clients benefit from a streamlined workflow, reduced biosafety concerns, and lower infrastructure requirements compared to conventional expression systems.
“The addition of this service reflects Lifeasible’s ongoing commitment to expanding its capabilities in plant biotechnology,” said Isla, a representative from Lifeasible. “By offering an efficient and adaptable expression system, we aim to support the growing demand for sustainable and reliable antibody production methods.”
The plant recombinant antibody expression service is intended for a broad range of applications, including therapeutic antibody development, diagnostic assay production, agricultural disease control, and environmental monitoring.
Lifeasible’s plant expression offerings form part of its larger service portfolio, which includes recombinant protein expression, gene editing, metabolic pathway analysis, and plant tissue culture services. The company provides full technical support throughout the project lifecycle.
For more information about this service, please visit: https://www.lifeasible.com/plant-recombinant-antibody-expression/.
